- Home
- IMAB vs IMUX Comparison
IMAB vs IMUX Comparison
Compare IMAB & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMAB
- IMUX
- Stock Information
- Founded
- IMAB 2014
- IMUX 2016
- Country
- IMAB United States
- IMUX United States
- Employees
- IMAB N/A
- IMUX N/A
- Industry
- IMAB Biotechnology: Pharmaceutical Preparations
- IMUX Biotechnology: Pharmaceutical Preparations
- Sector
- IMAB Health Care
- IMUX Health Care
- Exchange
- IMAB Nasdaq
- IMUX Nasdaq
- Market Cap
- IMAB 384.6M
- IMUX 90.4M
- IPO Year
- IMAB 2020
- IMUX N/A
- Fundamental
- Price
- IMAB $3.56
- IMUX $0.85
- Analyst Decision
- IMAB Strong Buy
- IMUX Strong Buy
- Analyst Count
- IMAB 5
- IMUX 5
- Target Price
- IMAB $6.80
- IMUX $7.50
- AVG Volume (30 Days)
- IMAB 1.7M
- IMUX 1.3M
- Earning Date
- IMAB 11-02-2025
- IMUX 11-06-2025
- Dividend Yield
- IMAB N/A
- IMUX N/A
- EPS Growth
- IMAB N/A
- IMUX N/A
- EPS
- IMAB N/A
- IMUX N/A
- Revenue
- IMAB N/A
- IMUX N/A
- Revenue This Year
- IMAB N/A
- IMUX N/A
- Revenue Next Year
- IMAB N/A
- IMUX N/A
- P/E Ratio
- IMAB N/A
- IMUX N/A
- Revenue Growth
- IMAB N/A
- IMUX N/A
- 52 Week Low
- IMAB $0.60
- IMUX $0.56
- 52 Week High
- IMAB $5.90
- IMUX $2.11
- Technical
- Relative Strength Index (RSI)
- IMAB 44.41
- IMUX 49.36
- Support Level
- IMAB $3.20
- IMUX $0.75
- Resistance Level
- IMAB $4.64
- IMUX $0.90
- Average True Range (ATR)
- IMAB 0.38
- IMUX 0.06
- MACD
- IMAB -0.16
- IMUX 0.00
- Stochastic Oscillator
- IMAB 28.19
- IMUX 65.16
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.